NCT07123090 2026-02-27
SPARCC
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07340658 2026-01-14
SIE-3
Rovi Pharmaceuticals Laboratories
Phase 3 Not yet recruiting
NCT07299890 2025-12-23
An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT07191977 2025-09-25
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
West China Hospital
Phase 2 Not yet recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06810492 2025-03-17
The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment
Hubei Cancer Hospital
Phase NA Not yet recruiting
NCT06757335 2025-01-03
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Hinova Pharmaceuticals Inc.
Phase 1/2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT05067530 2021-10-05
CAREGIVER
Medical University of Gdansk
Phase 2 Not yet recruiting
NCT04605562 2021-09-05
Umbrella Biomarker-Guided Therapy in NPC
Sun Yat-sen University
Phase 2 Not yet recruiting